🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Adagrasib 400 mg + Pembrolizumab impressive mPFS in KRAS G12C mutant NSCLC and PDL1 >50% and good safety. Better than IO or CT+IO alone. Good chemo free strategy for patients Await for ph3 trial. #ELCC2025

Time toxicity approach an important issue and Patient Reported Outcome for shared decisions in Oncology. #ELCC2025 #lcsm ⁦ESMO - Eur. Oncology⁩ ⁦OncoAlert⁩

What is the best ROS1 inhibitor ? Another money 💰 slide from ESMO - Eur. Oncology #ELCC2025

Interesting workflow giving rapid and equal access to lung cancer pts (regardless of origin/religion/social status) in Israel by Ory Wiesel #ELCC25 Medicine often better than politics.

> 3 yr follow up from the VISION study (METex14 mutated advanced NSCLC) treated with 🎯 tepotinib : 57.9% ORR, 12.6 m PFS in tt naive pts…. And still not reimbursed in France 😠#ELCC25

Great talk by ⁦Benjamin Besse⁩ on de-escalation strategies in oncology. Young fellow, if you missed it, check it on the #ELCC25 platform. We should change our mind and aim to de-escalade whenever possible.

#ELCC25 De-escalation clinical trials in NSCLC Impassioned presentation of the key trials, that can save pt’s time, toxicity, & ensure healthcare system sustainability - PULSE 🇫🇷 - Osi-Save 🇳🇱 - REFINE-Lung 🇬🇧 Benjamin Besse, best in the business ESMO - Eur. Oncology OncoAlert #LCSM

4 highlights #ELCC25: - relapses in BR.31 trial by Virginie Westeel - long-term 4y OS atezolizumab #SCLC by Lionel Falchero Nicolas Girard, - immunotherapy de-escalation #DIAL by Benjamin Besse - microenvironment #mesothelioma by Guillaume Tosato #LCSM ESMO - Eur. Oncology OncoAlert

#ELCC2025 is not yet over ! Great presentation by Sandra Ortiz-Cuaran on resistance to targeted therapies inn#NSCLC covering the heterogeneity of mechanisms. Key is probably to decipher the early drug tolerance state.

2 important consortiums to beat oncogene addicted #NSCLC : #BOLERO led by Sandra Ortiz-Cuaran dedicated to BRAF mutated lung cancer and #COALA (Cure Oncogene Addicted Lung Adenocarcinoma) funded by French national Institute. Looking forward to improving outcome of pts. #ELCC2025

Heterogeneity of resistance mechanisms should lead to personalized strategy to overcome resistance. Great and subtle presentation by Laura Mezquita #ELCC2025 “smart thinking” > same treatment/sequence for all.

Great Talk by Friboulet Luc highlighting the importance of understanding and targeting the residual disease in pts treated with targeted therapies. The message of this session is clear ! 🎯

Last brilliant and comprehensive talk by ⁦Roberto Ferrara⁩ on resistance to immunotherapy covering multiple strategies to overcome complex mechanisms of resistance. Towards perfect days ?? #ELCC2025. What a session !!! 👏👏👏

Novel ways to mitigate therapy toxicity in EGFR-mutant adv. NSCLC #ELCC2025 dailyreporter.esmo.org/european-lung-…

📢 J-1 avant le lancement du Trek Solid'AIR organisé par alk ros1 france cancer poumon avec le soutien IFCT du 2 au 11 avril ➡️Rdv demain à l' @APHM ou sur les 7 autres étapes du parcours : HCL - Hospices Civils de Lyon ICM CHRU de Nancy CHU de Besançon - Rejoignez-nous sur Bluesky CHU de Rouen Hôpital Tenon AP-HP IUCT Oncopole

1er colloque français sur le cancer du poumon à mutations rares : INSPIRE à pleins poumons 📆 Paris – les 9 & 10 nov 🤝 Patients, aidants, experts réunis pour 2 jours d’échanges, de savoirs & de rencontres. 🎟️ Programme et Inscriptions : colloqueinspire.teamresa.net

Bonne nouvelle pour la population, la santé publique et l’écologie. Déjà en place dans de nombreux pays.

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC : ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001 ✅ improved QoL (dyspnea and cough) ✅ 27% vs 62% G3 TRAEs Grateful to all collaborators, Amgen 🧪🔬🧬 science team and above all our pts

The FDA has approved taletrectinib for adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) — including those who have previously received ROS1 TKIs. A major advance for a rare molecular subtype of lung cancer. 🧵 🔹 What is taletrectinib? A

🔗 COALA project website is now live! 👉 coala-lung.org A national multidisciplinary consortium supported by the Institut national du cancer bringing together experts in lung cancer research to improve outcome of lung cancer patients with oncogenic addiction.